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Background: Direct patient-reported information about adverse drug events (ADEs) is important since it adds to
healthcare professional-reported information about the safety of drugs. Previously, we developed an instrument to
assess patient-reported ADEs in research settings. The aim of this study is to assess the construct and concurrent
validity of the questionnaire.
Methods: Patients on at least an oral glucose-lowering drug completed the ADE questionnaire, the World Health
Organization Quality of Life-BREF, and the Treatment Satisfaction Questionnaire for Medication (TSQM). The ADE
questionnaire assesses ADEs for any drug that the patient uses. Construct validity was assessed by testing whether
patients reporting an ADE had a lower general quality of life and physical health than those not reporting an ADE,
using Mann–Whitney U-tests and t-tests (significance level <0.05). For concurrent validity, we tested whether ADEs
that patients associate with particular drugs in the ADE questionnaire are documented in the Summary of Product
Characteristics (SPC) of those drugs, and whether patients who report an ADE with the use of metformin on the
TSQM, mention metformin as a drug associated with an ADE on the ADE questionnaire. Agreement of 70%
with the SPC was considered satisfactory. Sensitivity and positive predictive value (PPV) were calculated for the
comparison with the TSQM, where 70% was used as the cut-off level for sufficient concurrent validity.
Results: We included 135 patients (mean age 64 years, 35% women). Patients who reported an ADE (N = 37) had
a lower general quality of life and physical health than those not reporting an ADE (P < 0.05). For 78 of the 146
reported ADEs (53%), patients mentioned at least 1 particular drug associated with the ADE. After clustering
related ADEs, this resulted in 56 patient-reported ADE-drug associations. Of these, 41 (73%) were in agreement with
information in the SPC. Finally, the questionnaire had a sensitivity of 38% and PPV of 79% for assessing ADEs
associated with metformin.
Conclusions: The construct validity of the patient-reported ADE questionnaire was sufficient for reporting any
versus no ADE, but the concurrent validity was only partly demonstrated. Therefore, the questionnaire needs to
be adapted before it can be used.
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The safety of a drug is monitored and assessed in clinical
trials and observational studies [1,2]. Currently, the attri-
bution of adverse events to a drug and the assessment of
the severity of adverse drug events (ADEs) in research
settings is primarily conducted by healthcare profes-
sionals [3]. It has, however, been shown that healthcare
professionals downgrade the severity of ADEs experi-
enced by patients [4]. Additionally, it has been shown
that healthcare professionals underestimate symptom-
atic, subjective ADEs [4-7]. In a literature review, it was
for instance shown that ADE rates of constipation with
the use of the glucose-lowering drug metformin ranged
from 0.6-1.0% when reported by healthcare profes-
sionals, and was 21% when reported by patients [6].
Therefore, regulatory authorities acknowledge the added
value of patient-reported outcome instruments [8,9] in
which the patient is the direct source of information
[8,10]. This acknowledgement is especially the case for
many symptomatic ADEs for which there is no object-
ive test. Assessment of such ADEs is important, since
they influence a patient’s quality of life (QOL) [7]. Pre-
vious studies showed that an increase in total scores of
the number, frequency, and severity of experienced
ADEs is associated with a decrease in QOL [11,12]. In
addition, patients who report an ADE have a lower gen-
eral health perception than patients who do not report
an ADE [13].
Although some patient-reported instruments to assess
ADEs exist (e.g. [14-16]), a generic instrument not lim-
ited to a specific ADE, or drug, and including questions
about the nature (e.g. frequency, severity) and causality
is not available. Therefore, we previously developed such
an instrument [17]. This patient-reported ADE question-
naire is generic, checklist-based, includes questions about
the nature and causality of the ADE, and is intended
for research purposes in clinical trials and observational
studies. The content validity of the instrument has been
established and was adequate [17]. Further validation is
needed, in particular given reported concerns about the
validity of patient-reported ADEs (e.g. incorrect attribu-
tions of symptoms to drugs) [5].
The aim of the current study is to assess the construct
and concurrent validity of the patient-reported ADE
questionnaire. For the construct validity, the association
between patient-reported ADEs and QOL is tested.
With respect to the concurrent validity, the focus is on
(1) concurrence between reported ADE-drug associa-
tions and known ADEs of those drugs, and on (2)
agreement between ADE-drug reporting in the generic
ADE questionnaire and a treatment/drug-specific ques-
tionnaire with a differently phrased question. The re-
sults of this study will help to establish whether or not
the patient-reported ADE questionnaire is sufficientlyvalid to investigate experienced ADEs in clinical trials
and observational studies, and how to further improve
the questionnaire. More information about patient-
reported ADEs will increase the knowledge about the
safety of drugs, which in the end can be used in the de-
cision to approve or disapprove the drug to the market
and in clinical practice.
Methods
This study had a cross-sectional design and is part of a
larger study about the development and validation of the
patient-reported ADE questionnaire. For pragmatic rea-
sons, we focused on patients with type 2 diabetes, who
may be expected to use a variety of drugs with associ-
ated ADEs. Patients prescribed oral glucose-lowering
drugs were included in this study since that is a valid
proxy for type 2 diabetes. Previously, we have reported
on the development process of the ADE questionnaire
and assessment of its content validity and reliability [17].
We now present the follow-up study, assessing the con-
struct and concurrent validity of this questionnaire. For
this part, additional data were collected during the sec-
ond measurement of the previous study, assessing the
patients’ QOL and experiences with metformin, a drug
which was expected to be used by most of the included
patients (see below). The study was carried out in accord-
ance with the Code of Ethics of the World Medication
Association (Declaration of Helsinki) for experiments in-
volving humans. The Medical Ethics Committee of the
University Medical Center Groningen (METc UMCG) in
The Netherlands determined that ethical approval was not
needed for this study (reference number M12.112446).
Participants, procedure and data collection
Patients who were aged 18 years or older and had been
dispensed at least an oral glucose-lowering drug were re-
cruited in 2012 via pharmacists in the northern part of
The Netherlands, including two pharmacies in a village
and two in a town. The pharmacists selected patients
who fulfilled the inclusion criteria from their database
and sent an information letter with consent form to
these patients. One of the researchers (STdV) contacted
pharmacists until the number of consenting patients was
around 150. Those patients who had an e-mail address,
were able to access the internet, and gave informed con-
sent completed the ADE questionnaire twice with a one
week period in between. Patient characteristics reported
in the current study were based on patient-reported infor-
mation collected at the second measurement. The pharma-
cists provided prescription data covering a 1 year period
for all patients. They did this at one point in time, after
most patients had completed the second measurement.
Since chronic medication is prescribed for 3 months in
The Netherlands, the most recent prescriptions between 3
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tion were used to describe the medication prescribed to
the patients.
Measures
Patient-reported ADEs, ADE-drug associations, and causality
score
The patient-reported ADE questionnaire is a generic
questionnaire and contains a checklist with 252 symp-
toms, categorized in 16 body categories, which patients
can check as being a potential ADE for any of the drugs
they use [17]. Fourteen additional questions about its
nature are asked for each potential ADE, including ques-
tions about causality and causal drugs (e.g. “Of which
drug or drugs do you think this side effect is the re-
sult?”). Branching was used for these additional ques-
tions, which means that they were only presented if a
symptom was checked as being a potential ADE. Each
included symptom in the checklist is linked to a Lowest
Level Term of the Medical Dictionary for Regulatory Ac-
tivities (MedDRA®) terminology version 13.0. For the
current study, a web-based version of the questionnaire
was used which was constructed using the Unipark Enter-
prise Feedback Suite 8.0 version 1.1 [18]. Patients could
mention one or more than one drug to be associated with
one ADE in the questionnaire, for example, increased
stool frequency caused by metformin and tolbutamide.
Also, patients could mention the same drug or drugs for
multiple ADEs, for example decreased weight and abdom-
inal discomfort caused by liraglutide. Furthermore, pa-
tients could check multiple, related ADEs describing one
overall ADE, for example, diarrhea and fecal incontinence,
which they associated with the same drug or drugs. These
related ADEs were clustered by two researchers (STdV
and PD) independently [17]. This resulted in four possible
ADE-drug associations: single ADE-single drug, single
ADE-multiple drugs, clustered ADE-single drug, clustered
ADE-multiple drugs.
Quality of life
QOL was assessed using the Dutch version of the World
Health Organization Quality of Life-BREF (WHOQOL-
BREF) questionnaire [19]. The WHOQOL-BREF mea-
sures a patient’s QOL and contains 26 items, including
one item assessing general health, and one item asses-
sing general well-being. These two general items were
summed resulting in a general QOL score. The other
items comprise four domains of QOL, namely physical
health, psychological health, social relationships, and en-
vironment. An association between the ADE question-
naire and the general QOL score and physical health
domain were used as indicating construct validity of the
ADE questionnaire. The WHOQOL-BREF is a reliable
and valid questionnaire to measure QOL [20]. In ourstudy, the internal consistency ranged from .651 (domain
social relationships) to .836 (domain psychological health)
and was .806 for the physical health domain.
Known ADEs
Although there is no gold standard for which ADEs are
‘true’ ADEs, the ADEs that are documented in the Sum-
mary of Product Characteristics (SPC) can be considered
as known ADEs of a drug. Two researchers (STdV and
PD) independently determined whether all the patient-
reported ADE-drug associations (of both the single and
clustered ADEs) could be confirmed with the informa-
tion in the SPC as indicating concurrent validity. Dis-
similarities between the two researchers were resolved
by discussion. The SPCs of the reported drugs were
retrieved from the website of the Dutch Medicines
Evaluation Board [21].
The comparison of ADE-drug associations with the in-
formation in the SPC was additionally assessed by taking
into account a patient-reported causality assessment. We
developed a patient-reported causality scoring system
using the additional questions per potential ADE in the
questionnaire. This scoring system was based on the items
of the Naranjo causality classification [22], and patient-
reported aspects of causality assessment [23], and includes
the following items of the patient-reported ADE question-
naire: the question why the patient links the symptom to
drug use with the option to check more than one of the
answer categories assessing causality, the question which
drug the patient associates with the ADE, how certain the
patient is about this ADE-drug association, and the yes-no
question assessing whether or not the patient can think of
other reasons for experiencing the ADE. Scores could
range from −2 to +10 (Additional file 1).
Treatment/drug-specific ADEs
The Treatment Satisfaction Questionnaire for Medication
(TSQM) [24] was applied for the use of metformin. Met-
formin is the first-choice initial glucose-lowering drug in
the treatment of patients with diabetes [25,26], and likely
to be used by most of the patients included in our study.
Although the TSQM aims to assess treatment satisfaction,
the questionnaire contains four items about side effects.
One of these items asks for whether or not any ADE was
experienced as a result of taking the drug in question (“Do
you experience any side effects of the use of metformin?”).
The concurrent validity of the ADE questionnaire was ex-
amined by using the answers given to this question as the
gold standard and comparing them with the reporting of
metformin as a particular drug associated with an ADE in
the ADE questionnaire. Of note, no recall period is speci-
fied for this question in the TSQM. Patients who reported
that they had used metformin in the previous 4 weeks had
to complete the TSQM.
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The QOL of patients who reported one or more ADEs
and those who did not report an ADE in the patient-
reported ADE questionnaire was expressed with mean
and median scores and differences were tested using
Mann–Whitney U-tests (for non-normally distributed
variables, observed for general QOL in the study popu-
lation, where kurtosis was >1) and t-tests (physical
health, psychological health, social relationships, and
environment domains). Significance levels were used to
indicate sufficient validity, and effect-size of the differ-
ence in QOL was calculated to indicate clinical rele-
vance. We calculated effect-size as the (mean QOL of
those reporting ≥1 ADEs – mean QOL of those not
reporting an ADE) / standard deviation of the QOL scores
of those not reporting an ADE. Moderate (0.5 – 0.79)
or large (>0.8) effect-sizes were interpreted as clinically
relevant [27].
Differences in patient characteristics between those
who mentioned at least one particular drug for any of
their ADEs and those who did not mention a particular
drug for any of their ADEs were tested. In addition, dif-
ferences in ADE characteristics between the ADEs for
which patients mentioned at least one particular drug
and those ADEs for which patients did not mention a
particular drug were tested. T-tests, Fisher-Freeman-
Halton tests, and χ2-tests were used for these analyses.
The percentage of agreement was used in the compari-
son between the patient-reported ADE-drug association
and the information in the SPC of the drug. The per-
centage of agreement was calculated at the ADE level.
This calculation means that in case multiple drugs were
reported for one ADE, the confirmation that the ADE
was acknowledged in the SPC of at least one of the
drugs was considered as agreement in the analyses. We
did not expect full agreement between the patient-
reported ADE-drug associations and the information in
the SPC, since it has been demonstrated that some
ADEs are lacking in the SPC [28,29] and that patient-
reports may provide additional ADEs to those noted in
the SPC [5,30]. Therefore, we used a cut-off level of at
least 70% agreement between the patient-reported ADE-
drug associations and known ADEs as indicating sufficient
validity. A sensitivity analysis was performed in which the
patient-reported causality score was taken into account. In
this analysis, only the cases indicating a single ADE-single
drug association could be included, since the causality
score was measured at this level. We assessed the agree-
ment for all such cases, and for the cases with a causality
score higher than or equal to (1) the median of the causal-
ity scores, and (2) the third quartile.
For the comparison of the patient-reported ADE-
metformin association in the ADE questionnaire and the
TSQM, a positive outcome was defined as the detectionof an ADE with the use of metformin. The number of
true positives, true negatives, false positives, and false
negatives are presented. These numbers were used to
calculate the sensitivity [31] and positive predictive value
[32]. A cut-off level of 70% was used as indicating suffi-
cient sensitivity and/or positive predictive value. Most of
the patients on a drug are expected not to experience an
ADE which will result in a high number of true nega-
tives. Therefore, specificity and negative predictive value
were not calculated.
The analyses were conducted using IBM SPSS Statis-
tics version 20 (Armonk, New York, USA) and P-values
of <0.05 were considered statistically significant. Exact
confidence intervals based on binomial probabilities
were calculated for the validity measures [33], using
Stata version 12 (Stata Corp., College Station, TX).
Results
The number of patients included in this study was 135.
The mean age of these patients was 64 years (standard
deviation: 9), and most of them were male (65%) (Table 1).
Metformin was the most commonly prescribed oral
glucose-lowering drug (94%) and the median number of
total systemic drugs prescribed was 7 (interquartile range:
5–9). Thirty-seven patients (27%) reported at least one
ADE, with a total of 146 ADEs (median: 3, range: 1–11).
In 58% of the cases, the ADE had started more than 12
months ago. Most of the reported ADEs had not yet im-
proved or disappeared (82%).
Construct validity
Patients who reported one or more ADEs on the ques-
tionnaire had a lower self-reported QOL than patients
who did not report an ADE (Table 2). This difference
was statistically significant for physical health (P < 0.01),
and the general QOL score (P < 0.05), and turned out to
be clinically relevant (d = 0.53 for the general QOL score
and d = 0.50 for physical health). Although not statisti-
cally significant, patients who reported more than one
ADE (N = 26) had a lower general QOL score and phys-
ical health than those who reported one ADE (N = 11)
(median of 6.5 versus 8.0 on the general QOL score,
P = 0.032; mean of 13.6 versus 14.9 on physical health,
P = 0.138).
Concurrent validity
Comparison of patient-reported ADE-drug association with
known ADEs
For 78 reported ADEs (53%), patients mentioned at least
one particular drug for the ADE. These patients (N = 25)
did not significantly differ in age, gender, and education
level from the patients who did not mention a particular
drug for any of their ADEs (N = 12) (Additional file 2).
For the ADEs that were associated with one or more











Number of prescribed oral glucose-lowering drugsd
1 oral glucose-lowering drug 91 (68)
2 oral glucose-lowering drugs 38 (29)
3 oral glucose-lowering drugs 4 (3)
Classes of prescribed oral glucose-lowering drugsd
Biguanides 125 (94)
Dipeptidyl peptidase 4 (DPP-4) inhibitors 4 (3)
Glucagon-like peptide-1 (GLP-1) 5 (4)
Sulfonamides 42 (32)
Thiazolidinediones 3 (2)
Median number of systemic drugs prescribed (IQR) 7 (5–9)
Patients additionally on insulin 24 (18)
Patients reporting an ADE 37 (27)
Number of ADEs reported (range) 146 (1–11)
First time experiencing the ADE
Today 6 (4)
Yesterday 1 (1)
2-7 days ago 5 (3)
Between 1 week and 1 month ago 14 (10)
Between 1 and 6 months ago 14 (10)
Between 6 and 12 months ago 21 (14)
More than 12 months ago 85 (58)
ADE gone away or improved
Not yet 120 (82)
Clearly improved 14 (10)
ADE was treated and has improved 4 (3)
ADE went away by itself 0 (0)
ADE went away after quitting medication 1 (1)
ADE went away after treatment 1 (1)
Other 6 (4)
How much bothersome
Not at all 11 (8)
Only a bit 22 (15)
Somewhat 71 (49)
Quite a lot 31 (21)
Table 1 Patient characteristics and nature of the reported
ADEs (Continued)
Very much 11 (8)
Influence daily functioning
None 47 (32)
Only a bit 24 (17)
Somewhat 54 (37)
Quite a lot 18 (12)
Very much 2 (1)
ADEs = Adverse drug events; SD = Standard deviation;
IQR = Interquartile range.
aNo education; elementary school; junior secondary vocational education.
bJunior general secondary education; senior secondary vocational education.
cSenior general secondary education; higher professional education;
university education.
dMedication use is based on 133 patients since drug information of 2 patients
was not available.
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the ADE occurred (soon) after the start or dosage increase
of a drug and that a healthcare professional confirmed the
symptom being an ADE than for the ADEs not associated
with a particular drug (N = 68) (Additional file 3). ADEs
that were already perceived before the start of a drug but
increased in frequency after the start of a drug were less
likely to be associated with a particular drug. For 15% of
both ADEs, those that were associated with a particular
drug and those that were not, the patients reported that
the symptom was described in the patient leaflet as being
an ADE for that particular drug.
For almost half of the ADEs that were associated with
one or more particular drugs (38 cases; 49%), multiple re-
lated ADEs describing one overall ADE were observed
resulting in 16 clustered ADE-drug associations (Figure 1).
All of the single and clustered ADE-drug associations
(N = 56) were compared with the known ADEs for those
drugs as documented in the SPC (Additional file 4). In 41
of the cases (73%), the ADE-drug association was in agree-
ment with known ADEs for at least one of the reported
drugs, indicating sufficient concurrent validity.
There were 29 single ADE-single drug associations. Of
these ADEs, 22 (76%) were in agreement with the known
ADEs. The patient-reported causality score for these sin-
gle ADE-single drug associations ranged from 1 to 3
with a median of 2 (interquartile range: 1.0 – 2.5). The
single ADE-single drug associations with a causality as-
sessment score ≥2 (N = 21) were in 76% of the cases
(N = 16) in agreement with the known ADEs. This
agreement increased to 100% when only causality scores
of 3 (N = 7) were taken into account.
Comparison of ADE-metformin association between ADE
questionnaire and treatment/drug-specific questionnaire
Of the 135 patients, 125 reported that they had used
metformin in the previous 4 weeks. The comparison of
Table 2 QOL and differences between patients who report and those who do not report an ADE
Total Patients not reporting an ADE Patients reporting ≥1 ADEs P-value Effect size d
Number of patients 135 98 37
Mean QOL (SD)
Median general QOL score (IQR) 8.0 (6.0-8.0) 8.0 (7.0-8.0) 7.0 (6.0-8.0) .021† −0.53
Physical health 14.9 (2.5) 15.2 (2.4) 14.0 (2.6) .009* −0.50
Psychological health 14.7 (2.4) 15.0 (2.4) 14.1 (2.5) .064* −0.38
Social relationships 14.5 (2.6) 14.6 (2.7) 14.4 (2.6) .666* −0.07
Environment 16.0 (2.2) 16.2 (2.2) 15.6 (2.3) .134* −0.27
QOL = Quality of life; ADE = Adverse drug event; SD = Standard deviation; IQR = Interquartile range.
† =Mann–Whitney U-test; * = T-test.
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questionnaire and the TSQM revealed 11 true positives,
93 true negatives, 3 false positives, and 18 false nega-
tives. These numbers resulted in a sufficient, high posi-
tive predictive value (79%; 95% confidence interval 49-
95%), but an insufficient, low sensitivity (38%; 95% confi-
dence interval 21-58%).
Discussion
Construct validity of the ADE questionnaire was demon-
strated by an association between ADEs and QOL, where78 potential AD










Figure 1 Flow-chart of reported adverse drug events (ADEs) and ADEpatients who reported an ADE on the questionnaire had a
lower general QOL and physical health than patients who
did not report an ADE. The 73% agreement between the
ADE-drug associations as reported by the patients and the
known ADEs for those drugs as documented in the SPC
indicates concurrent validity. However, additional concur-
rent validity assessment revealed that the ADE question-
naire has sufficient positive predictive value but insufficient
sensitivity when comparing the linkage of an ADE to met-
formin in the ADE questionnaire with the treatment/drug-
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ADE had statistically significant lower scores than those
not reporting an ADE on physical health and on the
general QOL score. The lowest QOL scores were ob-
served for patients reporting more than 1 ADE. The ef-
fect sizes indicate that the QOL differences were
clinically relevant. The underlying mechanism for the as-
sociation between ADEs and QOL is not fully under-
stood yet. Although, an increase in the experience of
ADEs may be associated with a decrease in QOL
[11,12], it has also been shown that baseline QOL scores
were lower for patients who report an ADE at follow-up
than for patients who do not report an ADE at follow-
up [34]. This finding may imply that patients with a low
QOL have a higher risk of experiencing ADEs [35], or
that patients with negative health perceptions or certain
personality traits are more disposed to experiencing
and/or reporting ADEs [13,36]. The underlying mechan-
ism for the association between ADEs and QOL does
not influence its usefulness to assess construct validity,
since the principle of construct validity is based on the
existence of an adequate association between scores on
instruments [37].
Agreement of at least one drug that patients men-
tioned for their ADE on the patient-reported ADE ques-
tionnaire with known ADEs as documented in the SPC
supports its concurrent validity. Full agreement was
shown when only cases with a high patient-reported
causality score were included, indicating that a patient-
reported causality assessment increases the validity of
ADE reporting by patients. Previously, it was shown that
patients cannot perceive all ADEs and also do not always
make the connection between a symptom and their drug
use [7]. In addition, we found that only 53% of the pa-
tients who reported an ADE mentioned a particular drug
for the ADE. This low number may especially occur in a
patient population, such as included in this study. Pa-
tients with diabetes using oral glucose-regulating drugs
often use multiple drugs for various related and unre-
lated diseases, which complicates the assignment of a
drug to the symptom [38]. We found that mentioning a
particular drug was more likely when a healthcare pro-
fessional confirmed the symptom being an ADE. This
finding indicates that patient-reported ADE instruments
cannot fully replace healthcare professional reports. Spe-
cial attention of healthcare professionals may be neces-
sary for symptoms that are already present but increase
in frequency after starting a drug, and for ADEs that do
not occur soon after the start of a drug. Our study re-
sults support that for reliable knowledge about ADEs,
information from both healthcare professionals and pa-
tients is needed [39].
For 15% of the ADEs, the patients reported that the
ADE was described in the patient leaflet. Surprisingly,this was also observed for ADEs for which patients did
not mention a particular drug. It may be that the ADE is
reported in the patient leaflet of multiple drugs and the
patient is unsure about the exact drug that may cause
the ADE. Additional preferably qualitative research is
needed to better understand these reports.
Comparing the ADE questionnaire with the TSQM
only partly supported the concurrent validity. The posi-
tive predictive value indicates that an ADE with the use
of metformin detected by the ADE questionnaire is
likely to be an ADE. The low sensitivity, on the other
hand, implies that not all experienced ADEs associated
with metformin use are detected by the ADE question-
naire. There are, however, notable differences between
the ADE questionnaire and the TSQM that may nega-
tively influence the validity measures. First, the patient-
reported ADE questionnaire includes a recall period of 4
weeks whereas the TSQM does not include a recall
period. Second, in the patient-reported ADE question-
naire it is asked which drug is associated with the ADE,
whereas in the TSQM it is asked whether or not an
ADE is experienced with the use of the metformin.
More than half of the ADEs reported in this study
started more than 12 months ago. This timing of the
ADE may have influenced our validity assessment. For
construct validity, the experience of an ADE for a long
period of time may lead to a stronger association with
QOL due to the longer period of burden but could also
lead to a weaker association due to adaptation of getting
used to the symptoms. The timing of the ADE seemed
to influence whether or not a particular drug was men-
tioned for the ADE (Additional file 3). This finding indi-
cates that particularly the more recent ADEs were
included in the concurrent validity assessment, since
only patients who report a specific drug were included
in this assessment. It is not clear whether this could have
impact on the associations with the SPC and the TSQM
conducted for the concurrent validity.
An important limitation of this study is the low num-
ber of patients reporting an ADE. The construct validity
of the ADE questionnaire was only assessed by testing
the association between patient-reported ADEs and
QOL. Future studies should assess the construct validity
using additional constructs, also at specific ADE level
and taking the severity of the ADE into account. The se-
verity of an ADE has shown to influence a patient’s
QOL [35]. Participating patients in this study were sig-
nificantly younger than the nonresponders [17], and
were more often prescribed metformin and less often a
sulfonamide or thiazolidinedione than other, on average
elder, patients with diabetes in the Dutch primary care
[40]. These differences may be due to the use of a web-
based version of the questionnaire, because it has been
shown that respondents to web-based questionnaires are
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should also be noted that the validity of the paper-based
version of the questionnaire may differ from the web-
based version due to differences between these methods
in, for instance, branching of questions, visual aspects,
or respondent required actions such as the use of a
mouse in the web-based version [43-45]. Another limita-
tion was that about half of the reported ADEs that were
associated by the patients with particular drugs were
assessed by the researchers as being related ADEs de-
scribing one overall ADE. In this study, these ADEs were
clustered by the researchers. We recommend that future
research with checklist-based patient-reported ADE ques-
tionnaires should include the option for patients to cluster
related ADEs. This option will likely increase the validity of
the instrument and the practicability for the researchers.
We included patients using drugs for type 2 diabetes in this
study, who particularly reported ADEs belonging to the
gastrointestinal disorders SOC of the MedDRA® [17].
Although these patients also often used drugs for other dis-
eases, the use of the questionnaire in other patient popula-
tions and in the general population in which other ADEs
are also common requires additional validation [10]. The
validity of the questionnaire is expected to differ especially
for more serious ADEs (e.g. rhabdomyolysis with statin
use) and for ADEs that can be distinguished more clearly
from the symptoms related to the disease (e.g. alopecia
with the use of chemotherapy in patients with cancer).
Finally, it should be noted that this validation was con-
ducted in an observational study, where most patients were
current users and familiar with their drug treatment.
Therefore, additional studies are needed assessing the val-
idity of the instrument in a clinical trial, where patients are
often new users and blinded to the drug treatment. How-
ever, the insufficient concurrent validity indicates that the
first next step is to make adaptations to the questionnaire.
Conclusions
Our results indicate that the patient-reported ADE ques-
tionnaire has construct validity of reporting any ADE
versus no ADE, since the reporting of an ADE was asso-
ciated with a lower QOL. Additional assessment is
needed to test the construct validity for individual ADEs.
The concurrent validity was only partly demonstrated by
(1) sufficient agreement between the ADE-drug associa-
tions and the known ADEs when the researchers clus-
tered related ADEs into one ADE, (2) sufficient positive
predictive value to detect ‘real’ ADEs associated with
metformin use, but (3) insufficient sensitivity to detect
all ADEs that are associated with metformin use. There-
fore, adaptations to the ADE questionnaire, such as
allowing patients to cluster multiple related ADEs as
one overall ADE, need to be made and tested in future
validation studies.Additional files
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